Metronomic administration of ibandronate and its anti-angiogenic effects in vitro
- 31 December 2009
- journal article
- research article
- Published by Elsevier BV in Microvascular Research
- Vol. 78 (3), 453-458
- https://doi.org/10.1016/j.mvr.2009.07.004
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone diseaseZeitschrift für Krebsforschung und Klinische Onkologie, 2008
- Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer PatientsClinical Cancer Research, 2007
- Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasisBone, 2007
- Antitumor Effects of Clinical Dosing Regimens of Bisphosphonates in Experimental Breast Cancer Bone MetastasisJNCI Journal of the National Cancer Institute, 2007
- Enhanced expression of VEGF following bFGF inhibition in non-small cell lung cancer cell linesLung Cancer, 2006
- Cytosolic Entry of Bisphosphonate Drugs Requires Acidification of Vesicles after Fluid-Phase EndocytosisMolecular Pharmacology, 2006
- Ibandronate: A Clinical Pharmacological and Pharmacokinetic UpdateThe Journal of Clinical Pharmacology, 2004
- Pharmacokinetic and clinical equivalence of oral and intravenous ibandronate for metastatic bone diseaseEuropean Journal of Cancer Supplements, 2004
- Distinct regulation of genes by bFGF and VEGF-A in endothelial cells.Angiogenesis, 2001
- Experimental and Clinical Pharmacology: Bisphosphonates - mechanisms of actionAustralian Prescriber, 2000